Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes
There is limited published evidence on the use of olaparib in patients harboring pathogenic variants other than breast cancer genes, like PALB2 and ATM and conditions different than those authorized such as digestive tract, neuroendocrine and lung tumors. Further research is to assess the efficacy of olaparib in these patients.
Authors
- J Gómez-Alonso (ORCID: https://orcid.org/0000-0002-3102-1643)
- Anna Farriols
- Héctor Carlos García-Díaz (ORCID: https://orcid.org/0000-0002-1749-4751)
- Mara Cruellas (ORCID: https://orcid.org/0000-0002-6953-9675)
- Teresa Macarulla (ORCID: https://orcid.org/0000-0002-5856-4082)
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
- Maria J Carreras
- María Larrosa-Garcia
Institutions
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- Farmacia Hospitalaria
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1016/j.farma.2025.02.010
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05